MedElevator
Войти в исследования Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Termini Rosalinda, Žihala David, Terpos Evangelos, Perez-Montaña Albert, Jelínek Tomáš, Raab Marc, Weinhold Niels, Mai Elias K, Grab Anna Luise, Corre Jill, Vergez Francois, Sacco Antonio, Chiarini Marco, Giustini Viviana, Tucci Alessandra, Rodriguez Sara, Moreno Cristina, Perez Cristina, Maia Catarina, Martín-Sánchez Esperanza, Guerrero Camilla, Botta Cirino, Garces Juan-Jose, Lopez Aitziber, Tamariz-Amador Luis-Esteban, Prosper Felipe, Bargay Joan, Cabezudo Maria-Elena, Ocio Enrique M, Hájek Roman, Martinez-Lopez Joaquin, Solano Fernando, Iglesias Rebeca, Paiva Artur, Geraldes Catarina, Vitoria Helena, Gomez Clara, De Arriba Felipe, Ludwig Heinz, Garcia-Guiñon Antoni, Casanova Maria, Alegre Adrian, Cabañas Valentin, Sirvent Maialen, Oriol Albert, de la Rubia Javier, Hernández-Rivas José-Ángel, Palomera Luis, Sarasa Maria, Rios Pablo, Puig Noemi, Mateos Maria-Victoria, Flores-Montero Juan, Orfao Alberto, Goldschmidt Hartmut, Avet-Loiseau Hervé, Roccaro Aldo M, San-Miguel Jesus F, Paiva Bruno, PETHEMA/GEM and iMMunocell Cooperative Groups
Аннотация
EXPERIMENTAL DESIGN: We report the outcomes of 150 patients with SMM enrolled in the iMMunocell study, in which serial assessment of tumor and immune cells in PB was performed every 6 months for a period of 3 years since enrollment.
RESULTS: Patients with >0.015% versus ≤0.015% CTCs at baseline had a median time-to-progression of 17 months versus not reached (HR, 4.9; P < 0.001). Presence of >20% BM PCs had no prognostic value in a multivariate analysis that included serum free light-chain ratio >20, >2 g/dL M-protein, and >0.015% CTCs. The 20/2/20 and 20/2/0.015 models yielded similar risk stratification (C-index of 0.76 and 0.78). The combination of the 20/2/0.015 model with an immune risk score based on the percentages of SLAN+ and SLAN- nonclassical monocytes, CD69+HLADR+ cytotoxic NK cells, and CD4+CXCR3+ stem central memory T cells, allowed patient' stratification into low, intermediate-low, intermediate-high, and high-risk disease with 0%, 20%, 39%, and 73% rates of progression at 2 years.
CONCLUSIONS: This study showed that CTCs outperform BM PCs for assessing tumor burden. Additional analysis in larger series are needed to define a consensus cutoff of CTCs for minimally invasive stratification of SMM.